NetScientific PLC ProAxsis Presents New Data at Major US Conference
May 05 2017 - 1:01AM
RNS Non-Regulatory
TIDMNSCI
NetScientific PLC
05 May 2017
NetScientific plc
("NetScientific" or the "Company" or the "Group")
NetScientific Portfolio Company ProAxsis Presents New Data
Further Validating ProteaseTag(R) Technology at Major US
Conference
London, UK - 05 May 2017 - NetScientific plc (AIM:NSCI), the
transatlantic healthcare IP commercialisation Group, announces that
its portfolio company, ProAxsis, will be presenting further data on
its ProteaseTag(R) technology, at the American Thoracic Society
(ATS) Conference, which takes place between May 19(th) -24th in
Washington DC.
ProAxsis is developing a range of products for the capture,
detection and measurement of active protease biomarkers of disease.
ATS has accepted abstracts for the presentation of data on three
products being developed by ProAxsis in chronic diseases including
COPD, bronchiectasis and Cystic Fibrosis at the conference.
Commenting on the news, François R. Martelet, Chief Executive
Officer of NetScientific and Chairman of ProAxsis, said: "The broad
range of major disease indications covered in these studies
demonstrates the versatility of the ProteaseTag(R) technology being
developed by ProAxsis. We look forward to the continued development
of these exciting products and expect to see them commercially
available by the end of 2017."
The full text of the announcement issued by ProAxsis
follows:
ProAxsis abstracts at 2017 American Thoracic Society
Conference
Date: May 4, 2017
ProAxsis will be presenting further data on its ProteaseTag(R)
technology, at the American Thoracic Society Conference, which
takes place between May 19(th) -24th in Washington DC. The company
has had three abstracts accepted for presentation by the conference
review committee, details of which are below:
The Development of Novel ProteaseTags(R) for the Capture and
Disclosure of Mast Cell Tryptase
A34-CLINICAL AND CELLULAR STUDIES IN ALLERGIC DISEASE
Thematic Poster Session (presenting author Dr Timothy
Ferguson)
SUNDAY, MAY 21, 2017
9:15 AM-4:15 PM
The Development of a Novel ProteaseTag(R) Immunoassay for the
Detection and Quantification of Active Plasmin
C78-FIBROSIS: MEDIATORS AND MODULATORS
Thematic Poster Session (presenting author Dr Darragh
McCafferty)
TUESDAY, MAY 23, 2017
9:15 AM-4:15 PM
Development of NEATstik(R) - a Novel Lateral Flow Device for the
Detection of Active Neutrophil Elastase in Patients with
Respiratory Disease
C74-ADVANCES IN TRANSLATIONAL COPD
Thematic Poster Session (presenting author Dr Kelly Moffitt)
TUESDAY, MAY 23, 2017
9:15 AM-4:15 PM
Dr David Ribeiro, CEO of ProAxsis, said: "What I find most
exciting about the work we're presenting at this year's ATS
Conference is the variety. We're providing data on three of our
R&D products, all of which are expected to launch before the
end of 2017. Our first point-of-care test, NEATstik(R), has the
potential to re-invent how the risk of future exacerbations for
patients with long-term chronic diseases such as COPD,
bronchiectasis and CF, is monitored. We expect the active plasmin
immunoassay to act as a biomarker of fibrosis in diseases such as
IPF, and our tryptase assay should provide quantification of mast
cell involvement in diseases such as asthma and COPD. We're very
grateful to Invest Northern Ireland, who have supported our
development work on these two target proteases."
ProAxsis is part of the NetScientific group and is one of the
group's core portfolio companies. The company is also supported by
QUBIS, the commercialisation arm of Queens University.
To find out how ProAxsis can support the measurement of active
protease biomarkers of disease, or for any further queries, please
contact info@proaxsis.com
Ends
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet,
M.D., CEO
Ian Postlethwaite,
CFO
Consilium Strategic
Communications Tel: +44 (0)20 3709 5700
Mary-Jane Elliott Jessica netscientific@consilium-comms.com
Hodgson /
Chris Welsh / Laura
Thornton
Stifel Nicolaus Europe Tel: +44 (0) 20 7710 7600
Limited (NOMAD and Broker)
Jonathan Senior / David
Arch / Ben Maddison
About NetScientific
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases.For more
information, please visit the website at www.netscientific.net
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABIGDUUGGBGRS
(END) Dow Jones Newswires
May 05, 2017 02:01 ET (06:01 GMT)
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From May 2023 to May 2024